Core Viewpoint - The controversy surrounding the skincare brand "可复美" has led to a significant decline in the stock price of its parent company, 巨子生物, which has dropped 23% in just 10 trading days, resulting in a market value loss of over 21.2 billion HKD [2]. Group 1: Company Response and Actions - 巨子生物 announced on May 24 that it had commissioned multiple authoritative third-party testing agencies to verify the collagen content in its "重组胶原蛋白" products, but has yet to release the results [2]. - The company's IR department stated that the testing process is ongoing and results will be reported to the public as soon as they are available [2]. Group 2: Market and Competitive Dynamics - The controversy began when beauty blogger "大嘴博士" publicly questioned the actual collagen content in 可复美's core product, revealing it to be only 0.0177%, which contradicted the product's marketing claims [3]. - 巨子生物 responded to the allegations by asserting that the claims were "seriously inaccurate" and released self-test results showing collagen content exceeding 0.1% [3]. - The situation has been complicated by the involvement of competitor 华熙生物, which publicly supported the claims made by 大嘴博士, indicating a long-standing rivalry between the two companies [4]. - 华熙生物 has faced pressure in the market as its core product, "玻尿酸," has seen declining interest, while 巨子生物's "重组胶原蛋白" products have gained popularity, contributing to its rapid growth in both performance and market valuation [4].
可复美成分争议持续发酵，巨子生物市值蒸发超200亿港元，回应第三方检测进度